Previously, various types of specificity were designed, such as anti-CD33 AML [7, 25], anti-EpCAM against carcinomas [13], anti-CD19 against B-CLL [15] anti-TEM8 and anti-mesothelin against NSCLC [10, 27], anti-CLEC12A against AML [9], and anti-HER2 against ovarian cancer [26]. Here, CD19 is linked to acute myeloid leukemia.